Genenta Science S.p.A. (GNTA), Tuesday announced long-term follow-up data from its TEM-GBM study of Temferon in glioblastoma multiforme patients.
The study enrolled a total of 38 patients, with 25 patients receiving Temferon. Of this, two patients survived three years from the time of the first surgery.
The company noted that a 29 percent two-year survival rate for unmethylated MGMT patients, with median overall survival at 17 months. This is in comparison to patients receiving standard of care have shown a two-year survival rate of approximately 14 percent and a median overall survival of 13 to 15 months.
Also, the company has initiated the TEM-GU Phase 1 study, which intends to enroll 12 patients with genitourinary tumors, aiming to demonstrate the safety and tolerability of Temferon in patients with Metastatic Renal Cell Carcinoma by year-end.
In the pre-market hours, GNTA is moving up 11.99 percent, to $3.41 on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Health News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.